Biologics & Tides 2025

12 - 14 March 2025 | London, UK

Europe’s premier platform for facilitating partnerships and connecting leaders in the entire value chain of biologics & tides research and development

Overview Proteins & Antibodies Peptides Oligonucleotides Sustainability in Tides & Biologics

Explore Biologics & Tides 2025: Unlocking Future Insights in Biologics Research & Development

Join leaders, experts and researchers at Biologics & Tides 2025, connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in biologics discovery & development. Biologics & Tides 2025 features the co-location of Proteins & Antibodies, Peptides, Oligonucleotides and Sustainability in Tides & Biologics

Proteins & Antibodies

Join leading scientific experts within Proteins & Antibodies, addressing critical strategies and the latest technological advancements in antibody engineering, bioanalytical techniques as well as the latest case studies in the development of next-generation biotherapeutics.

  • New to 2025! Gain invaluable insights into novel strategies for cell line development & optimisation. Presentations will cover transposase mediated cell line generation, cell culturing techniques and advancing viral vector production through cell line development and engineering
  • Gain a comprehensive understanding of downstream development for antibodies and Fc containing molecules. From Intensifying processes to improve productivity and reduce processing time, through to addressing protein aggregation challenges and single use technologies
  • Discuss the latest novel tools & technologies for the display of biologics. Key opinion leaders will be presenting on addressing difficult targets with display technologies as well as developing novel in vitro display technologies for antibody discovery & engineering
  • Take a deep dive into novel clinical development strategies through engaging presentations on selecting patient population, ADC clinical development, designing clinical trials to get the best proof of concept & insights into non-oncology indications
  • Tap into the latest in ADC optimisation to enhance therapeutic potential through exciting sessions on linker / payload technologies, conjugation strategies and more

Agenda at a Glance


Day 1 | Track 1: Novel Tools & Technologies for the Display of Proteins & Antibodies

Day 1 | Track 2: ADC Design, Validation & Optimization to Enhance Their Therapeutic Potential

Day 1 | Track 3: Analytical Development: Stability & In-Depth Characterisation Methods for Proteins & Antibodies

Day 1 | Track 4: Novel Strategies for Cell Line Development & Expression Optimisation

Day 2 | Track 1: Antibody Discovery & Engineering

Day 2 | Track 2: New Formats: Cytokines & Immunocytokines

Day 2 | Track 3: Emerging Analytical Techniques, Developability & Quality Control Systems

Day 2 | Track 4: Downstream Development for Antibodies and Fc Containing Molecules

Day 3 | Track 1: AI/ML-Guided Protein & Antibody Engineering

Day 3 | Track 2: NextGen Multi-Specifics, Cell Engagers & Other New Modalities

Day 3 | Track 3: Novel Strategies for Clinical Development

Day 3 | Track 4: Novel Protein Process Development: Protein Purification & Recombinant Protein Production

Peptides

Peptides will bring together key experts in peptide chemistry and therapeutic development. With the latest technological advancements pushing the industry forward, join us in London to network, debate and discuss the pressing challenges & future opportunities.

  • New to 2025! Discuss the latest innovations in peptide therapeutics analysis. Key opinion leaders will cover the latest advancements in mass spec methods such as de novo sequencing & quantitative proteomics; AI/ML for therapeutics analysis and peptide sequencing
  • Stay at the forefront of peptide therapeutics research & development with hearing about novel targeted delivery methods, advances in peptide design and characterisation updates
  • Discover the latest innovations in peptide chemistry including advanced computational methods and the implementation of AI/ML technologies

Agenda at a Glance


Day 1 | Track 5: Peptide Discovery

Day 2 | Track 5: Peptide Chemistry

Day 3 | Track 5: Peptide Therapeutics & Development

Oligonucleotides

Join key opinion leaders, bringing about a new era of innovation in this field. Presentations will be covering computational approaches, methods & tools to oligonucleotide CMC as well as analytical control strategies for oligos.

  • New to 2025! Take a deep dive into oligo therapeutics analysis – from cell-based assay development through to improved computational methods, strategies & approaches including gene editors, CRISPR/CAS systems and guide RNA design
  • Discuss the latest therapeutic development success stories with thought-leaders presenting on immunogenicity considerations, progress to clinical trials and RNA targeting
  • Stay up-to-date with current advances in oligonucleotide delivery with presentations on nanoparticle technologies and conjugation strategies

Agenda at a Glance


Day 1 | Track 6: Oligo Discovery

Day 2 | Track 6: Oligo Chemistry & CMC

Day 3 | Track 6: Oligonucleotide Therapeutic Development & Optimisation

Sustainability in Tides & Biologics

Sustainability in Tides & Biologics addresses an important and expanding area, providing insights into driving sustainable innovation across biologics research & development; from sustainable synthesis approaches through to green manufacturing and sustainable supply chain processes.

  • New to 2025! Immerse yourself in innovations pertaining to peptide & oligo green chemistry, manufacturing and sustainable supply chain development. Presentations will delve into sustainable engineering practices, advanced solvent recovery systems and ensuring supply chain continuity
  • Express your thoughts on the future of solvent recovery systems and implementation of new sustainable manufacturing technologies, as well as taking a look at green manufacturing regulations
  • Explore the latest methodology in sustainable drug formulations including the usage of green and renewable APIs

Agenda at a Glance


Day 1 | Track 7: Peptides & Oligo Green Chemistry

Day 2 | Track 7: Green Innovations in Peptide & Oligo Manufacturing

Day 3 | Track 7: Towards Sustainable Supply Chain Development & Commercialisation for Biologics

ACROBiosystems Logo

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Genscript Logo

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Bioassay a Reaction Biology Company

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

ImmunoPrecise

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

What to Expect

1000

leading pharma, biotech, healthcare & academic delegates

50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including speed networking & refreshments
200
hours of pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership-1
What to Expect Global Technological Showcase-1
What to Expect Networking Emphasis-1
What to Expect Innovative Poster Displays-1

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Experience over 120 dynamic interactive discussions, C-level debates, collaborative roundtables, and thought-provoking presentations & innovation showcases curated with insights from top industry leaders and experts to benchmark your research & development pipeline
  • Global Technological Showcase

    An international & dynamic exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, personalised 1-2-1 meetings, a vibrant drinks reception, and informal gatherings to foster meaningful connections.
  • Innovative Poster Displays & Awards Ceremony

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and start-up companies.

Key Themes for Biologics & Tides 2025

The 2025 programmes will delve into the entire value chain of bringing a biologics and tides-based drug onto the market. Proteins & Antibodies will take a deep dive into the the latest developments ranging from antibody discovery through to analytical & clinical development, new formats & nextgen therapeutics approaches. The co-located Peptides and Oligonucleotides programmes examine the discovery and innovative chemistry approaches for peptides and oligos as well as therapeutic development & optimisation. Via Sustainability in Tides & Biologics, key opinion leaders will address moving towards sustainable supply chain development & commercialisation for biologics. Furthermore, the events facilitate C-level panel discussions & roundtables pertaining to the latest biologics discovery & development case studies - ranging form the pivotal role of designing ADC drugs to enhance their therapeutic potential to novel strategies for upstream & downstream development. 

Companies Represented Include

Biotech Innovation & Collaboration

Inspiring Tomorrow’s Breakthroughs: Unleashing Innovation & Collaboration in Biologics & Tides Research & Development

Join engaging presentations featured in our innovation and collaboration track running across the full event, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprised of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biologics discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers
  • Discovering new investment opportunities with pharma
  • Learning about the latest industry trends & challenges
  • Keeping updated with new innovations and technology solutions
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The Biologics & Tides Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biologics series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact help@oxfordglobal.com

Meet Our Expert Speakers

Biologics & Tides 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Darko Skegro
Associate Director,
Novartis
Fernando Albericio
Professor,
University of KwaZulu-Natal
Henry Maun
Associate Director,
Genentech
Joël Richard
Chief Development Officer,
Enterome
Kelly Loyet
Distinguished Scientist,
Genentech
Maja Firczuk
HT expression Team Leader,
GSK
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marta Amaral
Group Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Michal Shoshan
CEO and Founder,
metaLead Therapeutics AG
Reeta Daswani
Senior Scientist,
Sixfold
Simon Krah
Associate Director,
Merck Healthcare KgaA
Sudhir Agrawal
President & Founder,
ARNAY Sciences
Aaron John Balana
Scientist III,
Genentech
Alain Wagner
Director,
Strasbourg University
Alastair Lawson
Vice President and Immunology Fellow,
UCB
Alessandro Gori
Group leader,
National Research Council of Italy
Alexey Rak
Head of Bio Structure and Biophysics,
Sanofi
Álvaro Enríquez García
Medicinal chemist,
Eli Lilly
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Ana Pinho
Senior Manager, Sustainability,
BIAL
Andrew Slee
Chief Operating Officer,
Protagenic Therapeutics
Andrew Jamieson
Professor,
University of Glasgow
Andrew Buchanan
Principal Scientist,
AstraZeneca
Aneesh Karatt-Vellatt
CoFounder & CSO,
Maxion therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group leader of PeptLab,
University of Florence (Italy)
Aurelie Lacroix
Senior scientist,
Sixfold Bioscience
Bryce Nelson
Head Protein and Antibody Engineering,
Orion
Christopher Scott
Professor,
Queen's University Belfast
Christopher Hart
Chief Executive Officer,
Creyon Bio
Christopher Coxon
Senior Lecturer, Medicinal Chemistry,
THE UNIVERSITY OF EDINBURGH
Chun Kong Mak
Oligonucleotides Analytical Scientist,
Synthon
Dan Swerdlow
Senior Director,
GSK
Dan Hardy
CEO,
Microsol
Daniel Sejer Pedersen
Chemical Development Specialist CMC API Development,
Novo Nordisk
David Craik
Professor,
The University of Queensland
David Evans
Chief Scientific Officer,
Sirnaomics
David Brockwell
Professor,
University of Leeds
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Group Leader,
Byondis B.V.
Emma Grant
Senior Analytical Development Scientist,
Immunocore
Emma Stanley
Director, Program Lead - Head of Antibody Discovery,
Mestag Therapeutics
Erik Vernet
VP - Scientific Data Registration,
Novo Nordisk
Felix Schumacher
Program Leader Targeted Therapeutics,
Hoffmann La Roche Ltd
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Georgios Skretas
Director, Institute for Bioinnovation,
Biomedical Sciences Research Center "Alexander Fleming"
Hagen Cramer
Chief Production Officer,
QurAlis
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Ilaria Poledri
Co-Founder,
ExCulture
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jenny Fitting
Head of AAV and Protein Science,
Bayer
Jim Weterings
Vice President R&D USA,
Sirnaomics
John de Kruif
Executive Vice President & Chief Technology Officer,
Merus NV
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Komal Kedia
Associate Principal Scientist,
Merck US
Laura Starkie
Director,
UCB
Lauren Goodrich
Vice President Therapeutic Discovery,
Nimble Therapeutics
Laurens Lindenburg
Principal Scientist,
Genmab
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucas Bethge
VP, Group Leader Oligonucleotide Chemistry,
Silence Therapeutics
Luis Gómez-Morales
Scientific Project Manager,
Pepkon
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.
Marina Fedorova
Scientific Investigator,
GSK
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Michael Dyson
Vice President,
Ichnos SA
Michael Delaney
Principal Scientist,
NovoNordisk
Michelle Wantoch
Senior Scientist,
F-star Therapeutics Inc
Mikhail Kuravskiy
Principal Scientist,
UCB
Morten Lindow
RNAHub Founder & Mission Lead,
Roche
Nadim Akhtar
Senior Principal Scientist, New Modalities,
AstraZeneca
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Paul Reid
Co-Founder & Chief Executive Officer,
Celtic Biotech
Pawel Stocki
Vice President R&D,
Ossianix
Pete Gough
Chief Scientific Officer,
Nimble Therapeutics
Prasun Chakraborty
Founder & CEO,
Genevation
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
F. Hoffmann-La Roche Ltd
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Sarah Stuart
HTC Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saul Martinez Montero
Senior Director, RNA Therapeutics,
Dyne Therapeutics
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
Nucleic Acid Therapy Accelerator MRC
Stefan Zielonka
Director and Head of Antibody Discovery and Protein Engineering,
Merck Healthcare KGaA & Technische Universität Darmstadt
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & CEO,
Myria Biosciences
Talip Ucar
Senior Director - AI Research,
AstraZeneca
Tim Hickling
Investigative Safety and Immunosafety Chapter Lead,
Hoffmann La Roche Ltd
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Vladimir Gligorijevic
Senior Director of AI/ML,
Genentech
Walter Cabri
Full Professor of Organic Chemistry,
University of Bologna
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Director - Process Chemistry, CMC,
Bicycle Therapeutics
Yi Yang
Principal Scientist,
Ferring Pharmaceuticals A/S
Zahra Rattray
Senior Lecturer,
University of Strathclyde

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

FDA Fast Track ADC for Patients with Triple Negative Breast Cancer

The fast track designation means that the clinical development and regulatory milestones of the drug candidate are likely to progress much faster.

GSK Buys CureVac's mRNA Vaccine Business Providing Welcome Cash Injection

CureVac will continue to build its R&D pipeline while allowing GSK to develop and commercialise a handful of its prophylactic mRNA vaccines.

2002 Nobel Prize for Chemistry: Kurt Wüthrich, Using NMR to Determine the 3D Structure of Proteins

Kurt Wüthrich, joint winner of the 2002 Nobel Prize for Chemistry, contributed to the use of NMR to discover the 3D structure of proteins using sequential assignment and mathematical techniques.

Looking Back on the 2002 Nobel Prize for Chemistry: Mass Spectrometry for the Analysis of Proteins

2002's Nobel Prize for Chemistry recognised the translation of mass spectrometry to large molecules which has been instrumental in unlocking the proteome toward new therapies.

Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges

A concise report featuring insights from the prominent thought leaders of Biologics 2024

H5N1 Bird Flu Outbreaks: Effect on Vaccines

H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines.

Plan Your Visit

Novotel London West

1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air

London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus

Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail

The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car

Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biologics & Tides 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch